Table 1 Baseline characteristics of included studies
Author | Year | N | Sex(Male/Female) | Age | Disease status | Surgery | N in IMRT | N in 3D-CRT (Gy) | Dose of IMRT (Gy) | Dose of 3D-CRT | Fraction of IMRT | Fraction of 3D-CRT | Chemotherapy | Type | Stage (AJCC) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xin Wang [22] | 2016 | 100 | 82/28 | 55 (23–73) | stage IB-IIIC gastric cancer | curative resection with D2 lymph node dissection | 42 | 68 | 50.4 | 50.4 | 28 | 28 | 5-FU+ CDDP | RCT | IB-IIIC |
A. Yuriko Minn [29] | 2010 | 57 | 38/19 | 58 (29–83) | gastric or gastroesophageal junction cancer | Esophagogastrectomy, total or subtotal gastrectomy | 31 | 26 | 45 | 45 | 25 | 25 | 5-FU+ CDDP | RS | I-III |
Gene-Fu F. Liu [26] | 2014 | 24 | 18/6 | 56–64 | stage IB-IIIB gastric cancer | Esophagogastrectomy, total or subtotal gastrectomy | 12 | 12 | 50.4 | 45 | 25 | 25 | 5-FU | RS | IB-IIIC |
Boda-Heggemann J [12] | 2009 | 60 | 37/23 | 35–75 | gastric or gastroesophageal junction cancer | D2 resection | 33 | 27 | 45 | 45 | 25 | 25 | 5-FU+ CDDP | RS | I-IV |
Boda-Heggemann J [34] | 2013 | 65 | 38/27 | 35–76 | gastric or gastroesophageal junction cancer | total or subtotal gastrectomy | 38 | 27 | 45 | 45 | 25 | 25 | 5-FU+ CDDP | RS | I-IV |
Chopra S [23] | 2015 | 51 | 35/16 | 54 (25–74) | gastric or, proximal gastric and gastro-esophageal junction cancer | total or subtotal gastrectomy | 26 | 25 | 45 | 45 | 25 | 25 | Capecitabine | RS | I-III |
Goody, R. B. [35] | 2016 | 55 | 30/25 | 54 (28–77) | completely resected gastric cancer | total or subtotal gastrectomy | NA | NA | 45 | 45 | 25 | 25 | cisplatin | PS | I-III |
Fang, L. [25] | 2015 | 75 | 54/21 | 47 (31–58) | stage III-IV gastric cancer | curative resection | 25 | 25 | 45 | 45 | NA | NA | None | RCT | III-IV |
Deng, Q. H. [36] | 2011 | 29 | 23/6 | 55 (29–72) | stage III-IV gastric cancer | total or subtotal gastrectomy | 29 | 29 | 45 | 45 | 25 | 25 | None | RS | III-IV (UICC) |